Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRP | O00591 | 2/20 | 0.61 |
| ▸ | GABRD | O14764 | 2/20 | 0.61 |
| ▸ | GABRA1 | P14867 | 2/20 | 0.61 |
| ▸ | GABRB1 | P18505 | 2/20 | 0.61 |
| ▸ | GABRG2 | P18507 | 2/20 | 0.61 |
| ▸ | GABRB3 | P28472 | 2/20 | 0.61 |
| ▸ | GABRA5 | P31644 | 2/20 | 0.61 |
| ▸ | GABRA3 | P34903 | 2/20 | 0.61 |
| ▸ | GABRA2 | P47869 | 2/20 | 0.61 |
| ▸ | GABRB2 | P47870 | 2/20 | 0.61 |
| ▸ | GABRA4 | P48169 | 2/20 | 0.61 |
| ▸ | GABRE | P78334 | 2/20 | 0.61 |
| ▸ | GABRA6 | Q16445 | 2/20 | 0.61 |
| ▸ | GABRG1 | Q8N1C3 | 2/20 | 0.61 |
| ▸ | GABRG3 | Q99928 | 2/20 | 0.61 |
| ▸ | GABRQ | Q9UN88 | 2/20 | 0.61 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.45 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.45 |
| ▸ | ATR | Q13535 | 1/20 | 0.44 |
| ▸ | NOS3 | P29474 | 3/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL305494 | 0.83 | GABRP (0.54) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL4169682 | 0.81 | GABRP (0.56) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL8568260 | 0.79 | PSEN1 (0.43) | KMT2AKDM4EKDM5AKDM5CKDM5B | |
| SCHEMBL16114833 | 0.79 | KDM5A (0.43) | KMT2AKDM4EKDM5AKDM5CKDM5B | |
| SCHEMBL31661275 | 0.79 | GABRP (0.68) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL1159738 | 0.79 | GABRP (0.68) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL7287379 | 0.78 | KDM5A (0.42) | KMT2AKDM4EKDM5AKDM5CKDM5B | |
| SCHEMBL4926597 | 0.78 | TAS1R3 (0.44) | KMT2AKDM5AKDM5CKDM5BDDB1 | |
| SCHEMBL9363482 | 0.78 | KDM5A (0.42) | KMT2AKDM4EKDM5AKDM5CKDM5B | |
| Hydrochloric Acid SCHEMBL6227701 | 0.77 | GABRP (0.66) | GABRPGABRDGABRA1GABRB1GABRG2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2417120-B1 | SUBSTITUTED PIPERIDINES AS CCR3 ANTAGONISTS | BOEHRINGER INGELHEIM INT (DE) | 2016-10-26 | — | — | EP | disclosed |
| EP-1904494-B1 | IMIDAZO[1,2-A]PYRIDINE COMPOUNDS AS VEGF-R2 INHIBITORS | LILLY CO ELI (US) | 2010-12-01 | — | — | EP | disclosed |
| US-7666879-B2 | Imidazo[1,2-A]pyridine compounds as VEGF-R2 inhibitors | ELI LILLY AND COMPANY (US) | 2010-02-23 | — | — | US | disclosed |
| US-20090227622-A1 | IMIDAZO[1,2-A]PYRIDINE COMPOUNDS AS VEGF-R2 INHIBITORS | ELI LILLY AND COMPANY | 2009-09-10 | — | — | US | disclosed |
| EP-1904494-A1 | IMIDAZO[1,2-A]PYRIDINE COMPOUNDS AS VEGF-R2 INHIBITORS | ELI LILLY AND COMPANY (US) | 2008-04-02 | — | — | EP | disclosed |
| WO-2006091671-A1 | IMIDAZO (1, 2-A) PYRIDINE COMPOUNDS AS VEGF-R2 INHIBITORS | ELI LILLY AND COMPANY (US) | 2006-08-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090227622-A1 | IMIDAZO[1,2-A]PYRIDINE COMPOUNDS AS VEGF-R2 INHIBITORS | KDR, FLT1, FLT4 | GABRP 510/4885GABRD 2791/4885GABRA1 822/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.